T. Philip Malan, MD PhD

Vice Dean, Academic Affairs

Professor (With Tenure), Department of Anesthesiology

Professor, Department of Pharmacology

(520) 626-3867
malan@email.arizona.edu

View CV

Dr. Malan received a Bachelor of Science in Biological Sciences and a Bachelor of Arts in Chemistry in 1975 from the University of California, Irvine, California. He then pursued his PhD in Biochemistry and Molecular Biology from Harvard University, graduating in 1981. He attended medical school at the University of Massachusetts, receiving his Medical Degree in 1985. His internship year was done in Internal Medicine at the University of Massachusetts Medical Center, Worcester, Massachusetts. During his residency at Brigham and Women's Hospital, Boston, Massachusetts, from 1986 to 1989, he was also a Clinical Fellow in Anesthesia at Harvard Medical School. During his final year of residency, Dr. Malan was the Chief Resident in Anesthesia. He then joined the faculty at the University of Arizona College of Medicine, where he is now a Professor with tenure. In 1997, he also became an Associate Professor of Pharmacology, progressing to a Professor of Pharmacology in 2002. He is now the Vice Dean for Academic Affairs at the University of Arizona College of Medcine in Tucson, Arizona.

Research Interests:

• National Organization for Rare Disorders: “Spinal Neuropeptide Levels in Patients with Reflex Sympathetic Dystrophy”, 1998-1999
• National Institute on Drug Abuse / National Institutes of Health: “Non-Addicting Cannabinoid Medications” (R01 DA015866), 2003-2006
• Arizona Biomedical Research Commission: “Long-Term Activation of Pain-Enhancing Systems Following Short-Term Opioid Use”, 2005-2008
• National Institute on Drug Abuse / National Institutes of Health “Opioid and Non-Opioid Actions of Dynorplin in Pain”. (DA 11823), PI-Frank Porreca, 1998-2006
• National Institute on Drug Abuse / National Institutes of Health “Dynorphin and Opioid Tolerance”. (DA 12656), PI-Frank Porreca, 2000-2004
• National Institute on Drug Abuse / National Institutes of Health “RVM CCK and Opioid Tolerance”. (DA 15205), PI-Todd W. Vanderah, 2002-2007

Representative Publications:

Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP. CB2 cannabinoid receptor mediation of antinociception. Pain 2006; 122: 36-42.

Malan TP, Gordon S, Hubbard R, and Snabes M. The COX-2 Specific Inhibitor Parecoxib Sodium is as effective as 12 mg Morphine Administered Intramuscularly in the Treatment of Pain Following Gynecologic Laparotomy Surgery. Anesth Analg. 2005; 100: 454-60.

Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A. 2005; 102: 3093-8.

Malan TP, Gordon S, Hubbard R, and Snabes M. The COX-2 Specific Inhibitor Parecoxib Sodium is as effective as 12 mg Morphine Administered Intramuscularly in the Treatment of Pain Following Gynecologic Laparotomy Surgery. Anesth Analg. 2005; 100: 454-60.

Ibrahim MM, Deng H, Zvonok A, Cockayne DA Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not found in the central nervous system. Proc Natl Acac Sci, USA. 2003; 100: 10529-33.